ThinkStock PhotosShares of Aurobindo Pharma Ltd. rose 1.84 per cent to Rs 620.15 in Tuesday's trade. It hit an intraday high of Rs 621.6 and low of Rs 607.7, respectively, during the day.
The stock quoted a 52-week high price of Rs 1063.75 and low of Rs 584.2.
As of 10:51AM (IST), the counter saw total traded volume of 36,534 shares with a traded value of Rs 2.24 crore, according to NSE.
The stock had closed at Rs 608.95 in the previous session.
The scrip has declined -4.6 per cent in the past one month till date, while the benchmark BSE Sensex has slipped -7.94 per cent during the same period.
According to exchange data, the stock traded at a price-to-earnings (P/E) multiple of 12.66 while price-to-book ratio stood at 2.36. A higher P/E ratio shows that investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations. The price-to-book value indicates the inherent value of a company and it reflects the price investors are ready to pay even for no growth in a business.
The stock belongs to the Pharma - Indian industry.
Promoter/FII Holding
Promoters held 48.76 per cent stake in the company as of 31-Dec-2021, while FII and MF ownership in the firm stood at 21.37 per cent and 9.56 per cent, respectively.
Key Financials
The company reported consolidated sales of Rs 6067.21 crore for the quarter ended 31-Dec-2021, up 0.48 per cent from the previous quarter's Rs 6038.5 crore and up 6.63 per cent from the year-ago quarter's Rs 6498.31 crore. Its net profit for the latest quarter stood at Rs 604.73 crore, down 79.48 per cent from the same quarter a year ago.
The stock quoted a 52-week high price of Rs 1063.75 and low of Rs 584.2.
As of 10:51AM (IST), the counter saw total traded volume of 36,534 shares with a traded value of Rs 2.24 crore, according to NSE.
The stock had closed at Rs 608.95 in the previous session.
The scrip has declined -4.6 per cent in the past one month till date, while the benchmark BSE Sensex has slipped -7.94 per cent during the same period.
According to exchange data, the stock traded at a price-to-earnings (P/E) multiple of 12.66 while price-to-book ratio stood at 2.36. A higher P/E ratio shows that investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations. The price-to-book value indicates the inherent value of a company and it reflects the price investors are ready to pay even for no growth in a business.
The stock belongs to the Pharma - Indian industry.
Promoter/FII Holding
Promoters held 48.76 per cent stake in the company as of 31-Dec-2021, while FII and MF ownership in the firm stood at 21.37 per cent and 9.56 per cent, respectively.
Key Financials
The company reported consolidated sales of Rs 6067.21 crore for the quarter ended 31-Dec-2021, up 0.48 per cent from the previous quarter's Rs 6038.5 crore and up 6.63 per cent from the year-ago quarter's Rs 6498.31 crore. Its net profit for the latest quarter stood at Rs 604.73 crore, down 79.48 per cent from the same quarter a year ago.
Pick the best companies to invest
BECOME AN ETPRIME MEMBERRead More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by